Decellularized matrices for cardiovascular tissue engineering

American Journal of Stem Cells

Volumn 3, Issue 1, 2014, Pages 1-20

  Moroni, Francesco ^a   Mirabella, Teodelinda ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular; Decellularization; Matrix; Progenitors; Tissue engineering

Indexed keywords

DEOXYRIBONUCLEASE; DETERGENT; HYALURONIC ACID; MATRIX METALLOPROTEINASE; PROTEOCHONDROITIN SULFATE; PROTEOHEPARAN SULFATE; RIBONUCLEASE;

CARDIOVASCULAR DISEASE; CELL COMPONENT; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEART BLOOD VESSEL; HEART MUSCLE CELL; HEART VALVE; HEART VALVE REPLACEMENT; HUMAN; IMMUNE RESPONSE; NONHUMAN; OSMOTIC STRESS; PERICYTE; PROTEIN DEGRADATION; REVIEW; TISSUE ENGINEERING; TISSUE REGENERATION;

EID: 85008248810     PISSN: None     EISSN: 21604150     Source Type: Journal    
DOI: None     Document Type: Review

References (184)

1. Badylak SF, Freytes DO and Gilbert TW. Extracellular matrix as a biological scaffold material: Structure and function. Acta Biomater 2009; 5: 1-13.
2. Gilbert TW, Sellaro TL and Badylak SF. Decel-lularization of tissues and organs. Biomateri-als 2006; 27: 3675-3683.
3. McMurray JJ, Adamopoulos S, Anker SD, Auric-chio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trin-dade PT, Voors AA, Zannad F, Zeiher A; Bax JJ, Baumgart-ner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Paris-sis JT, Ponikowski P., Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology;; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Sch-reiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-e245.
5. Banner NR, Bonser RS, Clark AL, Clark S, Cow-burn PJ, Gardner RS, Kalra PR, McDonagh T, Rogers CA, Swan L, Parameshwar J, Thomas HL and Williams SG. UK guidelines for referral and assessment of adults for heart transplantation. Heart 2011; 97: 1520-1527.
6. Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, Mohacsi P, Augustine S, Aaronson K and Barr M. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candi-dates--2006. J Heart Lung Transplant 2006; 25: 1024-1042.
7. Vega JD, Moore J, Murray S, Chen JM, Johnson MR and Dyke DB. Heart transplantation in the United States, 1998-2007. Am J Transplant 2009; 9: 932-941.
8. Zimmermann WH, Melnychenko I and Eschen-hagen T. Engineered heart tissue for regeneration of diseased hearts. Biomaterials 2004; 25: 1639-1647.
9. Zimmermann WH, Melnychenko I, Wasmeier G, Didie M, Naito H, Nixdorff U, Hess A, Budin-sky L, Brune K, Michaelis B, Dhein S, Schwo-erer A, Ehmke H and Eschenhagen T. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 2006; 12: 452-458.
10. Shimizu T, Yamato M, Kikuchi A and Okano T. Cell sheet engineering for myocardial tissue reconstruction. Biomaterials 2003; 24: 2309-2316.
11. Radisic M, Deen W, Langer R and Vunjak-Nova-kovic G. Mathematical model of oxygen distribution in engineered cardiac tissue with parallel channel array perfused with culture medium containing oxygen carriers. Am J Physiol Heart Circ Physiol 2005; 288: H1278-1289.
12. Radisic M, Park H, Chen F, Salazar-Lazzaro JE, Wang Y, Dennis R, Langer R, Freed LE and Vun-jak-Novakovic G. Biomimetic approach to cardiac tissue engineering: oxygen carriers and channeled scaffolds. Tissue Eng 2006; 12: 2077-2091.
13. Park H, Radisic M, Lim JO, Chang BH and Vun-jak-Novakovic G. A novel composite scaffold for cardiac tissue engineering. In Vitro Cell Dev Biol Anim 2005; 41: 188-196.
14. Song JJ and Ott HC. Organ engineering based on decellularized matrix scaffolds. Trends Mol Med 2011; 17: 424-432.
15. Badylak SF, Lantz GC, Coffey A and Geddes LA. Small intestinal submucosa as a large diameter vascular graft in the dog. J Surg Res 1989; 47: 74-80.
16. Lantz GC, Badylak SF, Coffey AC, Geddes LA and Blevins WE. Small intestinal submucosa as a small-diameter arterial graft in the dog. J Invest Surg 1990; 3: 217-227.
17. Lantz GC, Badylak SF, Coffey AC, Geddes LA and Sandusky GE. Small intestinal submucosa as a superior vena cava graft in the dog. J Surg Res 1992; 53: 175-181.
18. Robinson KA, Li J, Mathison M, Redkar A, Cui J, Chronos NA, Matheny RG and Badylak SF. Extracellular matrix scaffold for cardiac repair. Circulation 2005; 112: I135-143.
19. Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, Netoff TI and Taylor DA. Perfusion-decellu-larized matrix: using nature's platform to engineer a bioartifcial heart. Nat Med 2008; 14: 213-221.
20. Soto-Gutierrez A, Wertheim JA, Ott HC and Gilbert TW. Perspectives on whole-organ assembly: moving toward transplantation on demand. J Clin Invest 2012; 122: 3817-3823.
21. Brinkley DM and Gelfand EV. Valvular heart disease: classic teaching and emerging paradigms. Am J Med 2013; 126: 1035-1042.
22. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG and Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368: 1005-1011.
23. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS; American College of Cardiology/American Heart Association Task Force on Practice G. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52: e1-142.
24. Brown JM, O'Brien SM, Wu C, Sikora JA, Griffth BP and Gammie JS. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg 2009; 137: 82-90.
25. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP and Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
26. Chikwe J, Filsouf F and Carpentier AF. Prosthetic valve selection for middle-aged patients with aortic stenosis. Nat Rev Cardiol 2010; 7: 711-719.
27. Human P and Zilla P. Infammatory and immune processes: the neglected villain of bio-prosthetic degeneration? J Long Term Eff Med Implants 2001; 11: 199-220.
28. Smedira NG, Blackstone EH, Roselli EE, Laffey CC and Cosgrove DM. Are allografts the biologic valve of choice for aortic valve replacement in nonelderly patients? Comparison of explantation for structural valve deterioration of allograft and pericardial prostheses. J Tho-rac Cardiovasc Surg 2006; 131: 558-564, e4.
29. Rippel RA, Ghanbari H and Seifalian AM. Tissue-engineered heart valve: future of cardiac surgery. World J Surg 2012; 36: 1581-1591.
30. Vesely I. Heart valve tissue engineering. Circ Res 2005; 97: 743-755.
31. Lam MT and Wu JC. Biomaterial applications in cardiovascular tissue repair and regeneration. Expert Rev Cardiovasc Ther 2012; 10: 1039-1049.
32. Dainese L, Guarino A, Burba I, Esposito G, Pompilio G, Polvani G and Rossini A. Heart valve engineering: decellularized aortic homo-graft seeded with human cardiac stromal cells. J Heart Valve Dis 2012; 21: 125-134.
33. Cigliano A, Gandaglia A, Lepedda AJ, Zinellu E, Naso F, Gastaldello A, Aguiari P, De Muro P, Gerosa G, Spina M and Formato M. Fine structure of glycosaminoglycans from fresh and de-cellularized porcine cardiac valves and pericardium. Biochem Res Int 2012; 2012: 979351.
34. O'Brien MF, Goldstein S, Walsh S, Black KS, El-kins R and Clarke D. The SynerGraft valve: a new acellular (nonglutaraldehyde-fxed) tissue heart valve for autologous recellularization frst experimental studies before clinical implantation. Semin Thorac Cardiovasc Surg 1999; 11: 194-200.
35. Simon P, Kasimir MT, Seebacher G, Weigel G, Ullrich R, Salzer-Muhar U, Rieder E and Wolner E. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg 2003; 23: 1002-1006; discussion 1006.
36. [36] Brown JW, Ruzmetov M, Eltayeb O, Rodefeld MD and Turrentine MW. Performance of Syner-Graft decellularized pulmonary homograft in patients undergoing a Ross procedure. Ann Thorac Surg 2011; 91: 416-422; discussion 422-413.
37. Perri G, Polito A, Esposito C, Albanese SB, Fran-calanci P, Pongiglione G and Carotti A. Early and late failure of tissue-engineered pulmonary valve conduits used for right ventricular outfow tract reconstruction in patients with congenital heart disease. Eur J Cardiothorac Surg 2012; 41: 1320-1325.
38. Konertz W, Angeli E, Tarusinov G, Christ T, Kroll J, Dohmen PM, Krogmann O, Franzbach B, Pace Napoleone C and Gargiulo G. Right ventricular outfow tract reconstruction with decel-lularized porcine xenografts in patients with congenital heart disease. J Heart Valve Dis 2011; 20: 341-347.
39. Dohmen PM. Clinical results of implanted tissue engineered heart valves. HSR Proc Intensive Care Cardiovasc Anesth 2012; 4: 225-231.
40. Hall MJ, DeFrances CJ, Williams SN, Golosins-kiy A and Schwartzman A. National Hospital Discharge Survey: 2007 summary. Natl Health Stat Report 2010; 1-20, 24.
41. Salacinski HJ, Goldner S, Giudiceandrea A, Hamilton G, Seifalian AM, Edwards A and Carson RJ. The mechanical behavior of vascular grafts: a review. J Biomater Appl 2001; 15: 241-278.
42. Liu SQ, Moore MM and Yap C. Prevention of mechanical stretch-induced endothelial and smooth muscle cell injury in experimental vein grafts. J Biomech Eng 2000; 122: 31-38.
43. Meng X, Mavromatis K and Galis ZS. Mechanical stretching of human saphenous vein grafts induces expression and activation of matrix-degrading enzymes associated with vascular tissue injury and repair. Exp Mol Pathol 1999; 66: 227-237.
44. Fitzpatrick JC, Clark PM and Capaldi FM. Effect of decellularization protocol on the mechanical behavior of porcine descending aorta. Int J Bio-mater 2010; 2010.
45. Klinkert P, Post PN, Breslau PJ and van Bockel JH. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg 2004; 27: 357-362.
46. Zhang L, Ao Q, Wang A, Lu G, Kong L, Gong Y, Zhao N and Zhang X. A sandwich tubular scaffold derived from chitosan for blood vessel tissue engineering. J Biomed Mater Res A 2006; 77: 277-284.
47. McClendon MT and Stupp SI. Tubular hydro-gels of circumferentially aligned nanofbers to encapsulate and orient vascular cells. Bioma-terials 2012; 33: 5713-5722.
48. Matsumura G, Nitta N, Matsuda S, Sakamoto Y, Isayama N, Yamazaki K and Ikada Y. Long-term results of cell-free biodegradable scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model. PLoS One 2012; 7: e35760.
49. Matsumura G, Isayama N, Matsuda S, Taki K, Sakamoto Y, Ikada Y and Yamazaki K. Long-term results of cell-free biodegradable scaffolds for in situ tissue engineering of pulmonary artery in a canine model. Biomaterials 2013; 34: 6422-6428.
50. Pankajakshan D and Agrawal DK. Scaffolds in tissue engineering of blood vessels. Can J Physiol Pharmacol 2010; 88: 855-873.
51. Kakisis JD, Liapis CD, Breuer C and Sumpio BE. Artifcial blood vessel: the Holy Grail of peripheral vascular surgery. J Vasc Surg 2005; 41: 349-354.
52. L'Heureux N, Dusserre N, Konig G, Victor B, Keire P, Wight TN, Chronos NA, Kyles AE, Gregory CR, Hoyt G, Robbins RC and McAllister TN. Human tissue-engineered blood vessels for adult arterial revascularization. Nat Med 2006; 12: 361-365.
53. Poh M, Boyer M, Solan A, Dahl SL, Pedrotty D, Banik SS, McKee JA, Klinger RY, Counter CM and Niklason LE. Blood vessels engineered from human cells. Lancet 2005; 365: 2122-2124.
54. Kelm JM, Lorber V, Snedeker JG, Schmidt D, Broggini-Tenzer A, Weisstanner M, Odermatt B, Mol A, Zund G and Hoerstrup SP. A novel concept for scaffold-free vessel tissue engineering: self-assembly of microtissue building blocks. J Biotechnol 2010; 148: 46-55.
55. Malone JM, Brendel K, Duhamel RC and Rein-ert RL. Detergent-extracted small-diameter vascular prostheses. J Vasc Surg 1984; 1: 181-191.
56. Lalka SG, Oelker LM, Malone JM, Duhamel RC, Kevorkian MA, Raper BA, Nixon JC, Etchberger KJ, Dalsing MC, Cikrit DF, et al. Acellular vascular matrix: a natural endothelial cell substrate. Ann Vasc Surg 1989; 3: 108-117.
57. Zou Y and Zhang Y. Mechanical evaluation of decellularized porcine thoracic aorta. J Surg Res 2012; 175: 359-368.
58. Schaner PJ, Martin ND, Tulenko TN, Shapiro IM, Tarola NA, Leichter RF, Carabasi RA and Dimuzio PJ. Decellularized vein as a potential scaffold for vascular tissue engineering. J Vasc Surg 2004; 40: 146-153.
59. Martin ND, Schaner PJ, Tulenko TN, Shapiro IM, Dimatteo CA, Williams TK, Hager ES and DiMuzio PJ. In vivo behavior of decellularized vein allograft. J Surg Res 2005; 129: 17-23.
60. Teebken OE, Puschmann C, Rohde B, Burgwitz K, Winkler M, Pichlmaier AM, Weidemann J and Haverich A. Human iliac vein replacement with a tissue-engineered graft. Vasa 2009; 38: 60-65.
61. Nelson CM and Bissell MJ. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2006; 22: 287-309.
62. Eddy AA. Molecular basis of renal fbrosis. Pe-diatr Nephrol 2000; 15: 290-301.
63. Ghosh AK, Quaggin SE and Vaughan DE. Molecular basis of organ fbrosis: potential therapeutic approaches. Exp Biol Med (Maywood) 2013; 238: 461-481.
64. Lockhart M, Wirrig E, Phelps A and Wessels A. Extracellular matrix and heart development. Birth Defects Res A Clin Mol Teratol 2011; 91: 535-550.
65. Mishra PK, Givvimani S, Chavali V and Tyagi SC. Cardiac matrix: A clue for future therapy. Biochim Biophys Acta 2013; 1832: 2271-2276.
66. [66] Howard CM and Baudino TA. Dynamic cell-cell and cell-ECM interactions in the heart. J Mol Cell Cardiol 2013; [Epub ahead of print].
67. [67] Davis J and Molkentin JD. Myofbroblasts: Trust your heart and let fate decide. J Mol Cell Car-diol 2013; [Epub ahead of print].
68. Toole BP. Hyaluronan in morphogenesis. Se-min Cell Dev Biol 2001; 12: 79-87.
69. Henderson DJ and Copp AJ. Versican expression is associated with chamber specifcation, septation, and valvulogenesis in the developing mouse heart. Circ Res 1998; 83: 523-532.
70. Kern CB, Twal WO, Mjaatvedt CH, Fairey SE, Toole BP, Iruela-Arispe ML and Argraves WS. Proteolytic cleavage of versican during cardiac cushion morphogenesis. Dev Dyn 2006; 235: 2238-2247.
71. Costell M, Carmona R, Gustafsson E, Gonza-lez-Iriarte M, Fassler R and Munoz-Chapuli R. Hyperplastic conotruncal endocardial cushions and transposition of great arteries in per-lecan-null mice. Circ Res 2002; 91: 158-164.
72. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H and Hynes RO. Defects in meso-derm, neural tube and vascular development in mouse embryos lacking fbronectin. Development 1993; 119: 1079-1091.
73. Moshal KS, Tyagi N, Moss V, Henderson B, Steed M, Ovechkin A, Aru GM and Tyagi SC. Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. J Cell Mol Med 2005; 9: 704-713.
74. Givvimani S, Tyagi N, Sen U, Mishra PK, Qip-shidze N, Munjal C, Vacek JC, Abe OA and Tyagi SC. MMP-2/TIMP-2/TIMP-4 versus MMP-9/ TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem 2010; 116: 63-72.
75. Mishra PK, Tyagi N, Sen U, Joshua IG and Tyagi SC. Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol. Cardiovasc Diabetol 2010; 9: 49.
76. Cleutjens JP. The role of matrix metalloprotein-ases in heart disease. Cardiovasc Res 1996; 32: 816-821.
77. Tyagi SC. Proteinases and myocardial extracellular matrix turnover. Mol Cell Biochem 1997; 168: 1-12.
78. Grant MA and Kalluri R. Structural basis for the functions of endogenous angiogenesis inhibitors. Cold Spring Harb Symp Quant Biol 2005; 70: 399-410.
79. Hinton RB and Yutzey KE. Heart valve structure and function in development and disease. Annu Rev Physiol 2011; 73: 29-46.
80. Schoen FJ. Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation 2008; 118: 1864-1880.
81. Vesely I. The role of elastin in aortic valve mechanics. J Biomech 1998; 31: 115-123.
82. Eckert CE, Fan R, Mikulis B, Barron M, Car-ruthers CA, Friebe VM, Vyavahare NR and Sacks MS. On the biomechanical role of gly-cosaminoglycans in the aortic heart valve leaflet. Acta Biomater 2013; 9: 4653-4660.
83. Krishnamurthy VK, Opoka AM, Kern CB, Guilak F, Narmoneva DA and Hinton RB. Maladaptive matrix remodeling and regional biomechanical dysfunction in a mouse model of aortic valve disease. Matrix Biol 2012; 31: 197-205.
84. Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG and Kaplan FS. Bone formation and infammation in cardiac valves. Circulation 2001; 103: 1522-1528.
85. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO and Spels-berg T. Human aortic valve calcifcation is associated with an osteoblast phenotype. Circulation 2003; 107: 2181-2184.
86. Grande-Allen KJ, Griffn BP, Ratliff NB, Cos-grove DM and Vesely I. Glycosaminoglycan pro-fles of myxomatous mitral leafets and chordae parallel the severity of mechanical alterations. J Am Coll Cardiol 2003; 42: 271-277.
87. Gupta V, Barzilla JE, Mendez JS, Stephens EH, Lee EL, Collard CD, Laucirica R, Weigel PH and Grande-Allen KJ. Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valves. Cardiovasc Pathol 2009; 18: 191-197.
88. Tamura K, Fukuda Y, Ishizaki M, Masuda Y, Ya-manaka N and Ferrans VJ. Abnormalities in elastic fbers and other connective-tissue components of foppy mitral valve. Am Heart J 1995; 129: 1149-1158.
89. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P and Schoen FJ. Activated interstitial myofbroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001; 104: 2525-2532.
90. Didangelos A, Yin X, Mandal K, Baumert M, Ja-hangiri M and Mayr M. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 2010; 9: 2048-2062.
91. Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol 1992; 27: 93-127.
92. Glover C, Ma X, Chen YX, Miller H, Veinot J, La-binaz M and O'Brien E. Human in-stent reste-nosis tissue obtained by means of coronary atherectomy consists of an abundant proteo-glycan matrix with a paucity of cell proliferation. Am Heart J 2002; 144: 702-709.
93. ER OB, Ma X, Simard T, Pourdjabbar A and Hib-bert B. Pathogenesis of neointima formation following vascular injury. Cardiovasc Hematol Disord Drug Targets 2011; 11: 30-39.
94. Glover C and O'Brien ER. Pathophysiological insights from studies of retrieved coronary atherectomy tissue. Semin Interv Cardiol 2000; 5: 167-173.
95. Rosenbloom J, Abrams WR and Mecham R. Extracellular matrix 4: the elastic fber. FASEB J 1993; 7: 1208-1218.
96. Arteaga-Solis E, Gayraud B and Ramirez F. Elastic and collagenous networks in vascular diseases. Cell Struct Funct 2000; 25: 69-72.
97. Morris CA. Genetic aspects of supravalvular aortic stenosis. Curr Opin Cardiol 1998; 13: 214-219.
98. Gray JR and Davies SJ. A clinical severity grading scale for Marfan syndrome. J Med Genet 1996; 33: 758-759.
99. [99] Segura AM, Luna RE, Horiba K, Stetler-Steven-son WG, McAllister HA Jr, Willerson JT and Fer-rans VJ. Immunohistochemistry of matrix me-talloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Circulation 1998; 98: 331-337; discussion II337-338.
100. Wagenseil JE and Mecham RP. Vascular extracellular matrix and arterial mechanics. Physiol Rev 2009; 89: 957-989.
101. Beighton P, De Paepe A, Steinmann B, Tsipou-ras P and Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet 1998; 77: 31-37.
102. Coen M, Gabbiani G and Bochaton-Piallat ML. Myofbroblast-mediated adventitial remodeling: an underestimated player in arterial pathology. Arterioscler Thromb Vasc Biol 2011; 31: 2391-2396.
103. Shi Y, Pieniek M, Fard A, O'Brien J, Mannion JD and Zalewski A. Adventitial remodeling after coronary arterial injury. Circulation 1996; 93: 340-348.
104. Bailey MT, Pillarisetti S, Xiao H and Vyavahare NR. Role of elastin in pathologic calcifcation of xenograft heart valves. J Biomed Mater Res A 2003; 66: 93-102.
105. Herbst TJ, McCarthy JB, Tsilibary EC and Furcht LT. Differential effects of laminin, intact type IV collagen, and specifc domains of type IV collagen on endothelial cell adhesion and migration. J Cell Biol 1988; 106: 1365-1373.
106. Gould DS and Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999; 20: 77-82.
107. Sanchez-Fueyo A and Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 2011; 140: 51-64.
108. Seetharam A, Tiriveedhi V and Mohanakumar T. Alloimmunity and autoimmunity in chronic rejection. Curr Opin Organ Transplant 2010; 15: 531-536.
109. Galvao FH, Soler W, Pompeu E, Waisberg DR, Mello ES, Costa AC, Teodoro W, Velosa AP, Capelozzi VL, Antonangelo L, Catanozi S, Martins A, Malbouisson LM, Cruz RJ Jr, Figueira ER, Filho JA, Chaib E and D'Albuquerque LA. Immu-noglobulin G profle in hyperacute rejection after multivisceral xenotransplantation. Xeno-transplantation 2012; 19: 298-304.
110. Schuurman HJ, Cheng J and Lam T. Pathology of xenograft rejection: a commentary. Xeno-transplantation 2003; 10: 293-299.
111. Oriol R, Ye Y, Koren E and Cooper DK. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation. Transplantation 1993; 56: 1433-1442.
112. Cooper DK, Good AH, Koren E, Oriol R, Malcolm AJ, Ippolito RM, Neethling FA, Ye Y, Romano E and Zuhdi N. Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immunol 1993; 1: 198-205.
113. Kuwaki K, Tseng YL, Dor FJ, Shimizu A, Houser SL, Sanderson TM, Lancos CJ, Prabharasuth DD, Cheng J, Moran K, Hisashi Y, Mueller N, Yamada K, Greenstein JL, Hawley RJ, Patience C, Awwad M, Fishman JA, Robson SC, Schuurman HJ, Sachs DH and Cooper DK. Heart transplantation in baboons using alpha1,3-ga-lactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11: 29-31.
114. Chen G, Qian H, Starzl T, Sun H, Garcia B, Wang X, Wise Y, Liu Y, Xiang Y, Copeman L, Liu W, Jevnikar A, Wall W, Cooper DK, Murase N, Dai Y, Wang W, Xiong Y, White DJ and Zhong R. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005; 11: 1295-1298.
115. Konakci KZ, Bohle B, Blumer R, Hoetzenecker W, Roth G, Moser B, Boltz-Nitulescu G, Gor-litzer M, Klepetko W, Wolner E and Ankersmit HJ. Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery. Eur J Clin Invest 2005; 35: 17-23.
116. Stone KR, Abdel-Motal UM, Walgenbach AW, Turek TJ and Galili U. Replacement of human anterior cruciate ligaments with pig ligaments: a model for anti-non-gal antibody response in long-term xenotransplantation. Transplantation 2007; 83: 211-219.
117. Stone KR, Ayala G, Goldstein J, Hurst R, Wal-genbach A and Galili U. Porcine cartilage transplants in the cynomolgus monkey. III. Transplantation of alpha-galactosidase-treated porcine cartilage. Transplantation 1998; 65: 1577-1583.
118. Hutter H, Vogel BE, Plenefsch JD, Norris CR, Proenca RB, Spieth J, Guo C, Mastwal S, Zhu X, Scheel J and Hedgecock EM. Conservation and novelty in the evolution of cell adhesion and extracellular matrix genes. Science 2000; 287: 989-994.
119. Elkins RC, Lane MM, Capps SB, McCue C and Dawson PE. Humoral immune response to al-lograft valve tissue pretreated with an antigen reduction process. Semin Thorac Cardiovasc Surg 2001; 13: 82-86.
120. Meyer SR, Nagendran J, Desai LS, Rayat GR, Churchill TA, Anderson CC, Rajotte RV, Lakey JR and Ross DB. Decellularization reduces the immune response to aortic valve allografts in the rat. J Thorac Cardiovasc Surg 2005; 130: 469-476.
121. Adair-Kirk TL and Senior RM. Fragments of extracellular matrix as mediators of inflamma-tion. Int J Biochem Cell Biol 2008; 40: 1101-1110.
122. Senior RM, Hinek A, Griffn GL, Pipoly DJ, Crouch EC and Mecham RP. Neutrophils show chemotaxis to type IV collagen and its 7S domain and contain a 67 kD type IV collagen binding protein with lectin properties. Am J Respir Cell Mol Biol 1989; 1: 479-487.
123. Adair-Kirk TL, Atkinson JJ, Broekelmann TJ, Doi M, Tryggvason K, Miner JH, Mecham RP and Senior RM. A site on laminin alpha 5, AQAR-SAASKVKVSMKF, induces inflammatory cell production of matrix metalloproteinase-9 and chemotaxis. J Immunol 2003; 171: 398-406.
124. Houghton AM, Quintero PA, Perkins DL, Ko-bayashi DK, Kelley DG, Marconcini LA, Me-cham RP, Senior RM and Shapiro SD. Elastin fragments drive disease progression in a mu-rine model of emphysema. J Clin Invest 2006; 116: 753-759.
125. Allman AJ, McPherson TB, Badylak SF, Merrill LC, Kallakury B, Sheehan C, Raeder RH and Metzger DW. Xenogeneic extracellular matrix grafts elicit a TH2-restricted immune response. Transplantation 2001; 71: 1631-1640.
126. Allman AJ, McPherson TB, Merrill LC, Badylak SF and Metzger DW. The Th2-restricted immune response to xenogeneic small intestinal submucosa does not influence systemic protective immunity to viral and bacterial pathogens. Tissue Eng 2002; 8: 53-62.
127. Chen N and Field EH. Enhanced type 2 and diminished type 1 cytokines in neonatal tolerance. Transplantation 1995; 59: 933-941.
128. Chen Y, Chen J, Liu Z, Liang S, Luan X, Long F, Peng Y, Yan L and Gong J. Relationship between TH1/TH2 cytokines and immune tolerance in liver transplantation in rats. Transplant Proc 2008; 40: 2691-2695.
129. Fujiwara N and Kobayashi K. Macrophages in infammation. Curr Drug Targets Infamm Allergy 2005; 4: 281-286.
130. Mills CD, Kincaid K, Alt JM, Heilman MJ and Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164: 6166-6173.
131. Mantovani A, Sica A and Locati M. Macrophage polarization comes of age. Immunity 2005; 23: 344-346.
132. Gordon S and Taylor PR. Monocyte and macro-phage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
133. Badylak SF and Gilbert TW. Immune response to biologic scaffold materials. Semin Immunol 2008; 20: 109-116.
134. Badylak SF, Valentin JE, Ravindra AK, McCabe GP and Stewart-Akers AM. Macrophage pheno-type as a determinant of biologic scaffold remodeling. Tissue Eng Part A 2008; 14: 1835-1842.
135. Ariganello MB, Simionescu DT, Labow RS and Lee JM. Macrophage differentiation and polarization on a decellularized pericardial biomate-rial. Biomaterials 2011; 32: 439-449.
136. Ariganello MB, Labow RS and Lee JM. In vitro response of monocyte-derived macrophages to a decellularized pericardial biomaterial. J Biomed Mater Res A 2010; 93: 280-288.
137. Brown BN, Ratner BD, Goodman SB, Amar S and Badylak SF. Macrophage polarization: an opportunity for improved outcomes in biomate-rials and regenerative medicine. Biomaterials 2012; 33: 3792-3802.
138. Brown BN, Londono R, Tottey S, Zhang L, Kukla KA, Wolf MT, Daly KA, Reing JE and Badylak SF. Macrophage phenotype as a predictor of constructive remodeling following the implantation of biologically derived surgical mesh materials. Acta Biomater 2012; 8: 978-987.
139. Martin I, Wendt D and Heberer M. The role of bioreactors in tissue engineering. Trends Bio-technol 2004; 22: 80-86.
140. Macchiarini P, Jungebluth P, Go T, Asnaghi MA, Rees LE, Cogan TA, Dodson A, Martorell J, Bellini S, Parnigotto PP, Dickinson SC, Hollander AP, Mantero S, Conconi MT and Birchall MA. Clinical transplantation of a tissue-engineered airway. Lancet 2008; 372: 2023-2030.
141. Go T, Jungebluth P, Baiguero S, Asnaghi A, Mar-torell J, Ostertag H, Mantero S, Birchall M, Bad-er A and Macchiarini P. Both epithelial cells and mesenchymal stem cell-derived chondro-cytes contribute to the survival of tissue-engineered airway transplants in pigs. J Thorac Cardiovasc Surg 2010; 139: 437-443.
142. Walles T, Puschmann C, Haverich A and Mertsching H. Acellular scaffold implantation-no alternative to tissue engineering. Int J Artif Organs 2003; 26: 225-234.
143. Kasimir MT, Weigel G, Sharma J, Rieder E, See-bacher G, Wolner E and Simon P. The decellu-larized porcine heart valve matrix in tissue engineering: platelet adhesion and activation. Thromb Haemost 2005; 94: 562-567.
144. Assmann A, Delfs C, Munakata H, Schiffer F, Horstkotter K, Huynh K, Barth M, Stoldt VR, Ka-miya H, Boeken U, Lichtenberg A and Akhyari P. Acceleration of autologous in vivo recellulariza-tion of decellularized aortic conduits by fbro-nectin surface coating. Biomaterials 2013; 34: 6015-6026.
145. Lu Q and Rounds S. Focal adhesion kinase and endothelial cell apoptosis. Microvasc Res 2012; 83: 56-63.
146. Ota T, Sawa Y, Iwai S, Kitajima T, Ueda Y, Cop-pin C, Matsuda H and Okita Y. Fibronectin-he-patocyte growth factor enhances reendotheli-alization in tissue-engineered heart valve. Ann Thorac Surg 2005; 80: 1794-1801.
147. Huang SD, Liu XH, Bai CG, Lu FL, Yuan Y, Gong DJ and Xu ZY. Synergistic effect of fbronectin and hepatocyte growth factor on stable cell-matrix adhesion, re-endothelialization, and re-constitution in developing tissue-engineered heart valves. Heart Vessels 2007; 22: 116-122.
148. Zhou M, Liu Z, Wei Z, Liu C, Qiao T, Ran F, Bai Y, Jiang X and Ding Y. Development and validation of small-diameter vascular tissue from a decellularized scaffold coated with heparin and vascular endothelial growth factor. Artif Organs 2009; 33: 230-239.
149. Miller-Kasprzak E and Jagodzinski PP. Endo-thelial progenitor cells as a new agent contributing to vascular repair. Arch Immunol Ther Exp (Warsz) 2007; 55: 247-259.
150. Rehman J, Li J, Orschell CM and March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107: 1164-1169.
151. Medina RJ, O'Neill CL, O'Doherty TM, Knott H, Guduric-Fuchs J, Gardiner TA and Stitt AW. My-eloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8. Mol Med 2011; 17: 1045-1055.
152. Tsai TN, Kirton JP, Campagnolo P, Zhang L, Xiao Q, Zhang Z, Wang W, Hu Y and Xu Q. Contribution of stem cells to neointimal formation of decellularized vessel grafts in a novel mouse model. Am J Pathol 2012; 181: 362-373.
153. Reing JE, Zhang L, Myers-Irvin J, Cordero KE, Freytes DO, Heber-Katz E, Bedelbaeva K, McIn-tosh D, Dewilde A, Braunhut SJ and Badylak SF. Degradation products of extracellular matrix affect cell migration and proliferation. Tissue Eng Part A 2009; 15: 605-614.
154. Mirabella T, Cilli M, Carlone S, Cancedda R and Gentili C. Amniotic liquid derived stem cells as reservoir of secreted angiogenic factors capable of stimulating neo-arteriogenesis in an ischemic model. Biomaterials 2011; 32: 3689-3699.
155. Mirabella T, Hartinger J, Lorandi C, Gentili C, van Griensven M and Cancedda R. Proangio-genic soluble factors from amniotic fuid stem cells mediate the recruitment of endothelial progenitors in a model of ischemic fasciocuta-neous fap. Stem Cells Dev 2012; 21: 2179-2188.
156. Mirabella T, Gentili C, Daga A and Cancedda R. Amniotic fuid stem cells in a bone microenvi-ronment: driving host angiogenic response. Stem Cell Res 2013; 11: 540-551.
157. Ng SL, Narayanan K, Gao S and Wan AC. Lineage restricted progenitors for the repopulation of decellularized heart. Biomaterials 2011; 32: 7571-7580.
158. Lu TY, Lin B, Kim J, Sullivan M, Tobita K, Sala-ma G and Yang L. Repopulation of decellular-ized mouse heart with human induced pluripo-tent stem cell-derived cardiovascular progenitor cells. Nat Commun 2013; 4: 2307.
159. Margariti A, Winkler B, Karamariti E, Zam-petaki A, Tsai TN, Baban D, Ragoussis J, Huang Y, Han JD, Zeng L, Hu Y and Xu Q. Direct repro-gramming of fbroblasts into endothelial cells capable of angiogenesis and reendothelializa-tion in tissue-engineered vessels. Proc Natl Acad Sci U S A 2012; 109: 13793-13798.
160. Mirsadraee S, Wilcox HE, Korossis SA, Kearney JN, Watterson KG, Fisher J and Ingham E. Development and characterization of an acellular human pericardial matrix for tissue engineering. Tissue Eng 2006; 12: 763-773.
161. Singelyn JM, Sundaramurthy P, Johnson TD, Schup-Magoffn PJ, Hu DP, Faulk DM, Wang J, Mayle KM, Bartels K, Salvatore M, Kinsey AM, Demaria AN, Dib N and Christman KL. Catheter-deliverable hydrogel derived from decellu-larized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol 2012; 59: 751-763.
162. Singelyn JM, DeQuach JA, Seif-Naraghi SB, Lit-tlefeld RB, Schup-Magoffn PJ and Christman KL. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials 2009; 30: 5409-5416.
163. Seif-Naraghi SB, Singelyn JM, Salvatore MA, Osborn KG, Wang JJ, Sampat U, Kwan OL, Stra-chan GM, Wong J, Schup-Magoffn PJ, Braden RL, Bartels K, DeQuach JA, Preul M, Kinsey AM, DeMaria AN, Dib N and Christman KL. Safety and effcacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med 2013; 5: 173ra125.
164. Wainwright JM, Czajka CA, Patel UB, Freytes DO, Tobita K, Gilbert TW and Badylak SF. Preparation of cardiac extracellular matrix from an intact porcine heart. Tissue Eng Part C Methods 2010; 16: 525-532.
165. Weymann A, Loganathan S, Takahashi H, Schies C, Claus B, Hirschberg K, Soos P, Kork-maz S, Schmack B, Karck M and Szabo G. Development and evaluation of a perfusion de-cellularization porcine heart model--generation of 3-dimensional myocardial neoscaffolds. Circ J 2011; 75: 852-860.
166. Akhyari P, Aubin H, Gwanmesia P, Barth M, Hoffmann S, Huelsmann J, Preuss K and Lich-tenberg A. The quest for an optimized protocol for whole-heart decellularization: a comparison of three popular and a novel decellulariza-tion technique and their diverse effects on crucial extracellular matrix qualities. Tissue Eng Part C Methods 2011; 17: 915-926.
167. [167] Oberwallner B, Brodarac A, Choi YH, Saric T, Anic P, Morawietz L and Stamm C. Preparation of cardiac extracellular matrix scaffolds by de-cellularization of human myocardium. J Biomed Mater Res A 2013; [Epub ahead of print].
168. [168] Leyh RG, Wilhelmi M, Rebe P, Fischer S, Kofdis T, Haverich A and Mertsching H. In vivo repopulation of xenogeneic and allogeneic acellular valve matrix conduits in the pulmonary circulation. Ann Thorac Surg 2003; 75: 1457-1463; discussion 1463.
169. Grauss RW, Hazekamp MG, Oppenhuizen F, van Munsteren CJ, Gittenberger-de Groot AC and DeRuiter MC. Histological evaluation of decellularised porcine aortic valves: matrix changes due to different decellularisation methods. Eur J Cardiothorac Surg 2005; 27: 566-571.
170. Erdbrugger W, Konertz W, Dohmen PM, Posner S, Ellerbrok H, Brodde OE, Robenek H, Moder-sohn D, Pruss A, Holinski S, Stein-Konertz M and Pauli G. Decellularized xenogenic heart valves reveal remodeling and growth potential in vivo. Tissue Eng 2006; 12: 2059-2068.
171. [171] Bloch O, Erdbrugger W, Volker W, Schenk A, Posner S, Konertz W and Dohmen PM. Extracellular matrix in deoxycholic acid decellular-ized aortic heart valves. Med Sci Monit 2012; 18: BR487-BR492.
172. Rieder E, Kasimir MT, Silberhumer G, See-bacher G, Wolner E, Simon P and Weigel G. Decellularization protocols of porcine heart valves differ importantly in effciency of cell removal and susceptibility of the matrix to recel-lularization with human vascular cells. J Tho-rac Cardiovasc Surg 2004; 127: 399-405.
173. Naso F, Gandaglia A, Formato M, Cigliano A, Lepedda AJ, Gerosa G and Spina M. Differential distribution of structural components and hydration in aortic and pulmonary heart valve conduits: Impact of detergent-based cell removal. Acta Biomater 2010; 6: 4675-4688.
174. Ota T, Taketani S, Iwai S, Miyagawa S, Furuta M, Hara M, Uchimura E, Okita Y and Sawa Y. Novel method of decellularization of porcine valves using polyethylene glycol and gamma irradiation. Ann Thorac Surg 2007; 83: 1501-1 5 07.
175. Honge JL, Funder JA, Jensen H, Dohmen PM, Konertz WF and Hasenkam JM. Recellulariza-tion of decellularized mitral heart valves in juvenile pigs. J Heart Valve Dis 2010; 19: 584-592.
176. Jordan JE, Williams JK, Lee SJ, Raghavan D, Atala A and Yoo JJ. Bioengineered self-seeding heart valves. J Thorac Cardiovasc Surg 2012; 143: 201-208.
177. Pellegata AF, Asnaghi MA, Stefani I, Maestroni A, Maestroni S, Dominioni T, Zonta S, Zerbini G and Mantero S. Detergent-enzymatic decellu-larization of swine blood vessels: insight on mechanical properties for vascular tissue engineering. Biomed Res Int 2013; 2013: 918753.
178. [178] Mangold S, Schrammel S, Huber G, Niemeyer M, Schmid C, Stangassinger M and Hoenicka M. Evaluation of decellularized human umbilical vein (HUV) for vascular tissue engineering - comparison with endothelium-denuded HUV. J Tissue Eng Regen Med 2012; [Epub ahead of print].
179. Gui L, Muto A, Chan SA, Breuer CK and Nikla-son LE. Development of decellularized human umbilical arteries as small-diameter vascular grafts. Tissue Eng Part A 2009; 15: 2665-2676.
180. Wilshaw SP, Rooney P, Berry H, Kearney JN, Homer-Vanniasinkam S, Fisher J and Ingham E. Development and characterization of acel-lular allogeneic arterial matrices. Tissue Eng Part A 2012; 18: 471-483.
181. Dahl SL, Koh J, Prabhakar V and Niklason LE. Decellularized native and engineered arterial scaffolds for transplantation. Cell Transplant 2003; 12: 659-666.
182. Pellegata AF, Asnaghi MA, Zonta S, Zerbini G and Mantero S. A novel device for the automatic decellularization of biological tissues. Int J Artif Organs 2012; 35: 191-198.
183. Quint C, Kondo Y, Manson RJ, Lawson JH, Dar-dik A and Niklason LE. Decellularized tissue-engineered blood vessel as an arterial conduit. Proc Natl Acad Sci U S A 2011; 108: 9214-9219.
184. Azhim A, Yamagami K, Muramatsu K, Morimo-to Y and Tanaka M. The use of sonication treatment to completely decellularize blood arteries: a pilot study. Conf Proc IEEE Eng Med Biol Soc 2011; 2011: 2468-2471.